Aclaris Therapeutics, Pediatrix Therapeutics Ink License Deal For ATI-1777 In Greater China
(RTTNews) - Biopharmaceutical company Aclaris Therapeutics, Inc. (ACRS) and Chinese therapeutic company Pediatrix Therapeutics, Inc. announced that the companies have entered into a license agreement.
Under the license agreement, Aclaris has granted Pediatrix the exclusive rights to develop, manufacture and commercialize ATI-1777, Aclaris' investigational "soft" Janus kinase (JAK) 1/3 inhibitor, for any disease, including atopic dermatitis, in Greater China (Mainland China, Hong Kong, Macau and Taiwan).
Aclaris will retain the rights to develop, manufacture and commercialize ATI-1777 in the rest of the world.
Under the terms of the agreement, Aclaris will receive an upfront payment of $5 million. In addition, Aclaris is eligible to receive milestone payments of up to $91 million if certain development, regulatory and commercial objectives are achieved.
Aclaris is also eligible to receive a tiered royalty ranging from a low-to-high single digit percentage of net sales of ATI-1777 by Pediatrix in Greater China.
For More Such Health News, visit rttnews.com
Aclaris Therapeutics Says Will Discontinue Further Development Of ATI-450 Program
Higher Open Called For China Stock Market
Rebound Anticipated For Taiwan Stock Market
Japan Retail Sales Add 0.3% In July
Singapore Stock Market May Add To Its Winnings On Friday
Japan Industrial Output Sinks 1.6% In July
Japan Jobless Rate Falls To 2.3% In July
